CEACAM5 and neoplasm: Several economically feasible blood markers have been explored in recent clinical studies to predict tumor regression response after NCRT, such as neutrophil to lymphocyte ratio (NLR), prognostic nutritional index (PNI), and carcinoembryonic antigen (CEA) (15–23).